Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Market Cap | $99 | $93 | $469 | $560 |
| - Cash | $54 | $9 | $40 | $77 |
| + Debt | $0 | $52 | $1 | $1 |
| Enterprise Value | $45 | $136 | $430 | $484 |
| Revenue | $0 | $1 | $3 | $3 |
| % Growth | -100% | -50.4% | 0% | – |
| Gross Profit | -$0 | $1 | $3 | $3 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$15 | $7 | -$37 | -$25 |
| % Margin | – | 546.3% | -1,368% | -926.3% |
| Net Income | -$19 | $6 | -$38 | -$22 |
| % Margin | – | 412.3% | -1,397.1% | -822.7% |
| EPS Diluted | -0.47 | 0.14 | -0.97 | -0.78 |
| % Growth | -435.7% | 114.4% | -24.4% | – |
| Operating Cash Flow | -$8 | -$10 | -$28 | -$21 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$8 | -$11 | -$28 | -$22 |